TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22820601

Group type: EXPERIMENTAL
Intervention: RhTPO (1.0 µg/kg) administered subcutaneously daily for 7 days starting 3 days before the second chemotherapy cycle (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RhTPO (1.0 µg/kg) administered daily for 7 days starting 6-24 hours after the second chemotherapy cycle (Group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control cycle (no RhTPO administered during the first chemotherapy cycle)
Number of subjects: 24
Study: 19919637

Group type: EXPERIMENTAL
Intervention: CMV‐IgG positive at the first trimester
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: CMV‐IgG seroconversion
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: CMV‐IgM seroconversion
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Both CMV‐IgG and CMV‐IgM positive
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Incidence of primary CMV infection during pregnancy
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Estimated incidence of congenital infection
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Congenital CMV infection
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Neurological sequelae in congenitally infected infants
Number of subjects: 339
Study: 18505112

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Without non-invasive ventilation (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 28
Study: 16595242

Group type: EXPERIMENTAL
Intervention: Laparoscopic chromopertubation with lipiodol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 88
Study: 12930046

Group type: EXPERIMENTAL
Intervention: Self‐administered Client Perceptions of Coordination Questionnaire
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Chronic pain syndromes
Number of subjects: 1193
Study: 10627419

Group type: EXPERIMENTAL
Intervention: Structured examination schedule for the diagnosis and classification of musculoskeletal disorders of the upper limb
Number of subjects: 88
Study: 9177592

Group type: EXPERIMENTAL
Intervention: Walking (6-week supervised program)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pain education program (instruction and demonstration of heat, cold, massage, relaxation, distraction)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study: 8241701

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (patients without coenzyme Q10 therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 120

Group type: COMPARATOR
Intervention: Patients with asymptomatic mitral valve prolapse
Number of subjects: 120
Study: 4089312

Group type: EXPERIMENTAL
Intervention: Acipimox (3 X 250 mg/day)
Number of subjects: 14
Study: 31100534

Group type: EXPERIMENTAL
Intervention: GIP (200 μg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-2 (800 μg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GIP(3-30)NH2 (800 pmol/kg/min) + GLP-2 (800 μg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30129904

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lumpectomy
Number of subjects: 40
Study: 26769876

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abstinence goal (all participants)
Number of subjects: 100
Study: 25383369

Group type: EXPERIMENTAL
Intervention: Electromyography-guided botulinum toxin injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fiberscopy-guided botulinum toxin injection
Number of subjects: 30
Study: 22490651

Group type: EXPERIMENTAL
Intervention: Mifepristone (various doses)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (no mifepristone)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Mifepristone (high dose)
Number of subjects: 101
Study: 20506004

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study: 17906182

Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet (mean 35 grams daily, 12% total energy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40
Study: 16135576

Group type: COMPARATOR
Intervention: 28-day cycle (standard regimen)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: 49-day cycle (every other month)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: 91-day cycle (every third month)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: 364-day cycle (continuous)
Number of subjects: 561
Study: 12188483

Group type: EXPERIMENTAL
Intervention: Injection of steroid (20 mg of triamcinolone with lignocaine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extracorporeal shock-wave therapy (2000 shock waves in three sessions at weekly intervals)
Number of subjects: 0
Study: 10457271

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily for 1 year)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 8543362

Group type: EXPERIMENTAL
Intervention: Broka's index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broka's index, BMI and weight for height (%)
Number of subjects: 0
Study: 2110559

Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 121639

Group type: EXPERIMENTAL
Intervention: Tinidazole (Fasigyn; Pfizer)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31970791

Group type: EXPERIMENTAL
Intervention: Clinical education program based on Watson's human caring theory
Number of subjects: 106
Study: 31298823

Group type: EXPERIMENTAL
Intervention: e-coaching and standard of care (SOC)
Number of subjects: 402

Group type: COMPARATOR
Intervention: standard of care (SOC)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: e-coaching and SOC
Number of subjects: 402
Study: 28650224

Group type: EXPERIMENTAL
Intervention: Structured organizational change intervention with external coaching based on the NIATx process improvement model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (baseline training about best practices in HIV testing)
Number of subjects: 0
Study: 25884452

Group type: EXPERIMENTAL
Intervention: Preventive home visits (up to three visits)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 278
Study: 24009027

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Composite scores 1 and 2
Number of subjects: 2293
Study: 21311196

Group type: EXPERIMENTAL
Intervention: Personalized computerized cognitive training
Number of subjects: 155

Group type: COMPARATOR
Intervention: Computer games
Number of subjects: 155
Study: 19284933

Group type: EXPERIMENTAL
Intervention: Vilazodone (10 mg to 40 mg once a day for 8 weeks)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 17591131

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia
Number of subjects: 874
Study: 15080853

Group type: EXPERIMENTAL
Intervention: Patient-directed intervention (direct mail)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 113
Study: 11699379

Group type: EXPERIMENTAL
Intervention: Active acupressure
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 97
Study: 9306077

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20mg/day for 14 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8392261

Group type: EXPERIMENTAL
Intervention: Essential fatty acids treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom-free controls
Number of subjects: 0
Study: 3595572

Group type: EXPERIMENTAL
Intervention: General anaesthesia (neurolept or halothane)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 24
Study: 31704382

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 535
Study: 28623089

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 0.5% (12.6mg) with 15μg fentanyl and 75μg morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 0.5% (6.0mg) with 15μg fentanyl and 75μg morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing doses of bupivacaine
Number of subjects: 0
Study: 24689952

Group type: EXPERIMENTAL
Intervention: Self-regulation intervention (theory-based instructional leaflets)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 155
Study: 26118157

Group type: EXPERIMENTAL
Intervention: Artesunate + Amodiaquine (AA group)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Artemether + Lumefantrine (AL group)
Number of subjects: 252
Study: 21806251

Group type: EXPERIMENTAL
Intervention: 9.6 μm CO2-laser irradiation (Pulse System Inc, Los Alamos, New Mexico), pulse duration 20 μs, pulse repetition rate 20 Hz, average fluence 4.1 ± 0.3 J/cm², 20 laser pulses per spot
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (nonirradiated area)
Number of subjects: 24
Study: 19459477

Group type: EXPERIMENTAL
Intervention: Pneumo 23 vaccine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (children born from HIV-negative women)
Number of subjects: 63
Study: 16896837

Group type: EXPERIMENTAL
Intervention: Single bond with methylene blue
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single bond with silver nitrate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with methylene blue
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with silver nitrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single bond and Clearfil SE Bond (both with methylene blue)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single bond and Clearfil SE Bond (both with silver nitrate)
Number of subjects: 40
Study: 15566506

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b plus ribavirin (100 microg once weekly and 800 mg/day orally)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Interferon alpha-2b plus ribavirin (3 million units thrice weekly and 800 mg/day)
Number of subjects: 96
Study: 11137745

Group type: EXPERIMENTAL
Intervention: Serum ECP measurement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eosinophil count
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference group (healthy subjects)
Number of subjects: 10
Study: 9117523

Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 7930741

Group type: EXPERIMENTAL
Intervention: Sowdah type onchocerciasis
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Generalized form of onchocerciasis
Number of subjects: 92

Group type: COMPARATOR
Intervention: Endemic normal persons
Number of subjects: 92

Group type: COMPARATOR
Intervention: Nonexposed persons
Number of subjects: 92
Study: 3336176

Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied to forearm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied to face
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle cream applied to forearm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle cream applied to face
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical tretinoin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 30
Study: 28303421

Group type: EXPERIMENTAL
Intervention: Group Coping Power
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Individual Coping Power
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: A/A genotype
Number of subjects: 197
Study: 28167746

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home exercise programme (Control)
Number of subjects: 0
Study: 26665460

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by muscle injection 30 min before the operation followed by saline every 24 h for 48 h (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by muscle injection 30 min before the operation followed by 40 mg every 24 h for 48 h (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.9% saline at the same time points (Control Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both Group A and Group B
Number of subjects: 120
Study: 23905652

Group type: EXPERIMENTAL
Intervention: Black pepper (2.0 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rosemary (1.7 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (3.1 g rice flour)
Number of subjects: 40
Study: 21692235

Group type: EXPERIMENTAL
Intervention: Lornoxicam (LNX) 8 mg
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (DP) 50 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (PLAC) cellulose powder
Number of subjects: 114
Study: 19446402

Group type: EXPERIMENTAL
Intervention: ACTION smoking cessation program
Number of subjects: 260

Group type: COMPARATOR
Intervention: Comparison participants (control group)
Number of subjects: 260
Study: 16375852

Group type: EXPERIMENTAL
Intervention: Reinstatement group (one or four unpredicted UCS-only trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no additional UCS presentations)
Number of subjects: 0
Study: 14727000

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 175

Group type: COMPARATOR
Intervention: Fluoxetine 30 mg daily
Number of subjects: 175
Study: 11395188

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg/day for 3 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 20
Study: 9223109

Group type: EXPERIMENTAL
Intervention: Cytocidal IgM anti-Fas mAb
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antagonistic anti-FasR mAb
Number of subjects: 0
Study: 8425445

Group type: EXPERIMENTAL
Intervention: Lactose challenge (2 g/kg) in lactose-intolerant children
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lactose challenge (2 g/kg) in normal children
Number of subjects: 110
Study: 2906174

Group type: COMPARATOR
Intervention: Nifedipine 10 mg four times daily plus placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg four times daily plus famotidine 40 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once daily
Number of subjects: 12
Study: 29289727

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (1150 ppm) + Fluoride mouthrinse (220 ppm)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (1150 ppm) + No rinse
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Placebo dentifrice + Fluoride mouthrinse (220 ppm)
Number of subjects: 53
Study: 27020873

Group type: EXPERIMENTAL
Intervention: Orthodontic bands on first permanent molars
Number of subjects: 25

Group type: COMPARATOR
Intervention: Directly bonded tubes on the labial surface of first permanent molars
Number of subjects: 25
Study: 25917680

Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 23758929

Group type: EXPERIMENTAL
Intervention: INVOS monitoring
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: INVOS monitoring (intention to treat analysis)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (intention to treat analysis)
Number of subjects: 150
Study: 21963834

Group type: EXPERIMENTAL
Intervention: Neck suction (NS; carotid hypertension) at -60 Torr
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neck pressure (NP; carotid hypotension) at +40 Torr
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neck pressure (NP; carotid hypotension)
Number of subjects: 40
Study: 19808280

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training at 70% of peak o(2) 3 times a week for 8 weeks (group E, n=44)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Waltz dancing protocol (group D, n=44)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (group C, n=42)
Number of subjects: 130
Study: 21937568

Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone prolonged-release tablets (OXN PR)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Oxycodone prolonged-release tablets (OxyPR)
Number of subjects: 185
Study: 16054413

Group type: EXPERIMENTAL
Intervention: GH treatment (subcutaneous injections of GH 0.03 IU/kg/daily) for 5 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IGF-I treatment (continuous subcutaneous infusion of 5 microg/kg/h recombinant IGF-I) for 5 days
Number of subjects: 6
Study: 12056182

Group type: EXPERIMENTAL
Intervention: Fresh young coconut water (CW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte beverage (CEB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Plain water (PW)
Number of subjects: 8
Study: 9522112

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 7877347

Group type: EXPERIMENTAL
Intervention: Carbimazole (decreasing doses)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Carbimazole (high doses) plus Levothyroxine
Number of subjects: 76
Study: 1688617

Group type: EXPERIMENTAL
Intervention: MACOP-B chemotherapy regimen (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MACOP-B chemotherapy regimen
Number of subjects: 70
Study: 82144

Group type: EXPERIMENTAL
Intervention: Aspirin prophylaxis
Number of subjects: 12
Study: 12117628

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 680

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 680
Study: 31297962

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 6278

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 6278

Group type: COMPARATOR
Intervention: ICIs plus chemotherapy
Number of subjects: 6278
Study: 30165522

Group type: EXPERIMENTAL
Intervention: Training in communication skills
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Training in CRP testing
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Training in both CRP testing and communication skills
Number of subjects: 5

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5
Study: 26915737

Group type: EXPERIMENTAL
Intervention: Explicit training condition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Implicit training condition
Number of subjects: 80
Study: 24626141

Group type: EXPERIMENTAL
Intervention: Block Start (BS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rhythm Step (RS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Forward Step (FS)
Number of subjects: 16
Study: 22268699

Group type: EXPERIMENTAL
Intervention: Fractionated CO2 laser therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 2
Study: 20214154

Group type: EXPERIMENTAL
Intervention: Zygote intrafallopian transfer (ZIFT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Uterine embryo transfer (UET)
Number of subjects: 220
Study: 17570634

Group type: EXPERIMENTAL
Intervention: Echocardiographic guidance with MitraClip
Number of subjects: 47
Study: 15726120

Group type: EXPERIMENTAL
Intervention: EoP (Cisplatin plus oral etoposide); etoposide 50 mg p.o. twice a day for 7 days, cisplatin 70 mg/m² i.v. on day 1, repeated every 3 weeks.
Number of subjects: 201

Group type: COMPARATOR
Intervention: Paclitaxel; 175 mg/m² i.v. on day 1, repeated every 3 weeks.
Number of subjects: 201
Study: 12799102

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with conjugated estrogen and medroxyprogesterone for 3 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-HRT control group
Number of subjects: 28
Study: 10372237

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (10% fat, 4% saturated)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High monounsaturated fat (MUFA) diet (32% fat, 7% saturated)
Number of subjects: 35

Group type: COMPARATOR
Intervention: High saturated fat (SFA) diet (32% fat, 17% saturated)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Energy restriction (1,600 kcal/day for 12 weeks)
Number of subjects: 35
Study: 8888304

Group type: EXPERIMENTAL
Intervention: Full-body clips
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upright biological-motion displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverted biological-motion displays
Number of subjects: 0
Study: 1839161

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 6848680

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 31345964

Group type: EXPERIMENTAL
Intervention: ASSIST 1.0 intervention programme (theory-based reablement programme including coaching of home care staff and digitally based smart products)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study: 30128952

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 53
Study: 27890050

Group type: EXPERIMENTAL
Intervention: Interprofessional medication management
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 142